Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)Seeking Alpha • 09/12/23
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory PapillomatosisPRNewsWire • 09/07/23
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 08/29/23
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/09/23
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic UpdatePRNewsWire • 08/09/23
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsGlobeNewsWire • 06/23/23
Inovio Pharmaceuticals, Inc. (INO) Jefferies Healthcare Conference 2023 (Transcript)Seeking Alpha • 06/09/23
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionPRNewsWire • 05/23/23
Inovio Pharmaceuticals, Inc. (INO) 2023 RBC Capital Markets Global Healthcare Conference (Transcript)Seeking Alpha • 05/17/23
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/23
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023PRNewsWire • 05/08/23
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023PRNewsWire • 04/27/23
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107PRNewsWire • 04/26/23